Flat/rangebound — $137.85, −3.9% off 52-wk high, just above 50/200-DMA, RSI 72 (overbought), +8.9% 12-mo (SPY +20.6%)
Conviction
Low — 0 expert voices, 0 KB claims; the thesis rests on fundamentals and quant, not a panel
Position sizing
If owned, a small defensive/income sleeve, ~1–2% — a ballast holding, not a conviction bet
Next catalyst
2026-07-23 Q2'26 earnings (Street EPS $3.24)
Single biggest risk
Catastrophe / reserve-development tail — a bad CAT year or an adverse legacy-liability reserve charge
One-line thesis. The Hartford is a disciplined, cheap (9.5× earnings), low-beta P&C-plus-benefits insurer earning a 20% core ROE — a genuinely high-quality operator, but it trades right on top of the Street's target with only single-digit upside, so it is a Watch: own it for ballast and yield if you already do, but there is no valuation edge or expert conviction to underwrite a fresh buy here.
◆ Synthos call — HoldHIG is a solid business largely reflected at ~$150 — fine to keep, no reason to chase; it gets interesting again below ~$128.
Downside Risk (lower = safer)
3/10 · Low
Low beta (0.48), net-debt/EBITDA 0.75×, 9.5× earnings — cheap & sturdy; cyclical CAT/reserve tail is the real risk.
Growth Quality
5/10 · Moderate
~4-5% forward revenue CAGR, high-teens/low-20s EPS growth off buybacks, 20% core ROE — solid, not exciting.
Exponential Potential
2/10 · Low
Mature P&C insurer at fair value; growth decelerating, no acceleration, no room-to-run multibagger.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 10%/yrTo justify today’s $138, earnings would have to compound roughly 10% a year for 10 years (9% discount rate). Analysts forecast ~15%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
The Hartford sells insurance to businesses and families — workers' comp, commercial property and liability, car and home insurance, plus group life and disability benefits sold through employers, and a small mutual-fund arm. It has been doing this since 1810.
The business is run well and the stock is cheap: you pay only about $9.50 for every $1 the company earns in a year (most stocks cost far more), and the company earns a strong return on the money shareholders leave in it. So why not a screaming "Buy"? Because the price has already caught up to what it's worth — the stock sits right at the average Wall Street price target, so the easy money is likely made. Our verdict is Watch: a fine, steady company at a fair — not bargain — price.
Here's what our three scores mean in everyday terms:
Downside Risk 3/10 (fairly safe). Cheap, low-debt, and its stock barely swings with the market — but insurers can get hit by a bad hurricane year or by having to set aside more money for old claims.
Growth Quality 5/10 (solid, middle of the road). It grows slowly but reliably and is very profitable; it just isn't a fast grower.
Exponential Potential 2/10 (low). This is a mature, big, slow-and-steady insurer. Do not expect it to double quickly — that's not what it is.
The one big worry: insurance is cyclical and lumpy. A severe catastrophe season (hurricanes, wildfires, winter storms) or a surprise charge to cover decades-old liability claims can dent a year's profit fast.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = HIG · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$137.85
Market cap$38B
P/E trailing6×
P/E FY26E / FY27E11× / 10×
EV / Sales1.5×
EV / EBITDA7.4×
Gross margin47.0%
Net margin14.1%
Dividend yield1.68%
Beta0.475
52-wk range$120 – $144
RSI(14)72
50 / 200-DMA$133 / $134
12-mo return+9% (SPY +21%)
Street target$150 ($135–$165)
Analyst grades24 Buy · 18 Hold · 0 Sell
FMP ratingA
Next earnings2026-08-05
What the experts actually said 0 traceable claims on HIG · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
The Hartford Insurance Group (NYSE: HIG) is a ~215-year-old US property-and-casualty insurer with a benefits and asset-management arm. It reports in five segments: Business Insurance (commercial P&C — workers' comp, property, liability, package, the growth engine), Personal Insurance (auto and homeowners), Property & Casualty Other Operations (legacy asbestos/environmental run-off), Employee Benefits (group life and disability sold through employers), and Hartford Funds (managed mutual funds and ETFs). Fiscal year ends December 31. CEO Christopher Swift; CFO Beth Costello.
Revenue mix (from filings & the Q1'26 release):
FMP's product/geographic segmentation for HIG is stale (the granular product breakout it carries is from 2011–2013 and a single 2022 line — not usable for a current mix), so we lean on the FY25 financials and the Q1'26 earnings release instead. FY25 total revenue was $28.26B, of which roughly $15.2B is captured as cost-of-revenue (claims/benefits incurred), with net investment income a material earnings driver ($739M pre-tax in Q1'26 alone).
The business is overwhelmingly US, with a modest UK/international footprint. The old FMP geo file (Japan-heavy, 2011–2013) reflects a divested legacy Japan variable-annuity book and is not representative of today's US-centric P&C company.
Segment signal (Q1'26): Business Insurance written premium +6%, combined ratio 94.8 (underlying 89.2 — a sub-90 underlying is strong); Personal Insurance combined ratio 87.7 (improved sharply as auto/home loss ratios fell); Employee Benefits core-earnings margin 6.9%. Business Insurance is the durable profit center.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert thesis to report. The Synthos knowledge base contains zero claims on HIG (total_claims: 0, 0 net-bullish voices). No distilled expert — bullish or bearish — covers this name in our KB.
This is stated plainly because honesty is the product: this verdict is entirely fundamentals- and quant-driven, built from the FMP financials, analyst estimates, the company's own SEC earnings release, and standard insurance metrics. It carries no conviction premium from expert breadth — which is exactly why the conviction rating is Low and the verdict is a Watch rather than a high-conviction Buy. Where a name like this could earn an upgrade is a genuine valuation dislocation or an expert catalyst; today it has neither.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
3 · Low-Moderate
9.5× TTM earnings, P/B 2.0×, net-debt/EBITDA 0.75×, beta 0.48, shallow −3.9% drawdown — cheap and sturdy. Held off a 2 only by insurance's inherent CAT/reserve cyclicality and a legacy sexual-abuse reserve tail (a $70M Q1'26 top-up).
Mature $38B P&C insurer; growth decelerating (FY26E EPS actually dips below FY25 before recovering), no acceleration, no TAM room-to-run. This is ballast, not a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Benign CAT years, Business Insurance keeps 6%+ premium growth at sub-90 underlying, buybacks shrink the share count. FY27E EPS beats to ~$15.5; the market pays a ~11.5× multiple for a proven 20% ROE compounder.
~$178 (+29%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$14.15; a steady low-double-digit compounder holds its historical ~10.5× multiple.
~$150 (+9%)
Bear
A severe CAT season and/or a fresh adverse legacy-liability reserve charge; Personal Insurance competition pressures growth. FY27E EPS misses to ~$12.2; multiple de-rates to ~9×.
~$110 (−20%)
Synthos fair value = the base case, ~$150 (+9%), with the full $110–$178 span as the honest range. Our base sits essentially on top of the Street's $150.38 consensus — which is itself a tell: there is no dislocation here to exploit. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HIG is a respectable compounder with essentially no exponential character:
Forward growth: revenue CAGR FY25→FY28E ~3.6% ($28.3B → $31.4B); EPS is lumpier — FY26E consensus $12.83 actually sits below FY25's $13.32 diluted (a modest reset), recovering to $14.15 (FY27E) and $15.40 (FY28E). Call it high-single/low-double-digit EPS growth, largely helped by a shrinking share count (buybacks).
Acceleration (the 2nd derivative) is flat-to-negative: revenue grew +7.1% (FY25) and decelerates to ~+3–4% forward. There is no inflection; this is a steady-state mature insurer.
Room to run: the US P&C/benefits market is enormous but slow-growing and share-stable; HIG is already a top-tier scaled writer. At $38B market cap a 5× would imply ~$190B — implausible for a mature domestic insurer. Growth is capped by the category, not by capital.
Reinvestment runway: capital returns dominate — $617M returned in Q1'26 ($450M buybacks + $167M dividends). This is a return-capital, not reinvest-for-growth, story — the opposite of an exponential.
Exponential Potential: Low (2/10). Own HIG (if at all) for a ~20% ROE, cheap multiple, low beta and steady capital return — not for growth. Honest framing: this belongs in a defensive/income sleeve, never a moonshot tier.
Revenue: FY25 $28.26B, +7.1% (FY24 $26.38B, +8.4% on FY23 $24.33B). Steady mid-single-digit top-line, driven by earned-premium growth and higher net investment income.
Quarterly trajectory: Q1'25 $6.81B → Q2 $6.99B → Q3 $7.23B → Q4 $7.31B → Q1'26 $7.23B. Flat-to-up sequentially; no acceleration, but no deterioration either.
Underwriting margin (the real insurance tell): Business Insurance underlying combined ratio 89.2 and Personal Insurance 85.0 in Q1'26 — both comfortably sub-90, i.e. profitable underwriting before investment income. Business Insurance premium +6%.
Earnings: FY25 net income $3.82B ($13.32 diluted EPS); Q1'26 net income to common $851M (+36% YoY), core earnings $866M (+36%), $3.09 core EPS. Note Q1'26 reported EPS of $3.09 missed the $3.39 estimate — worth watching.
Profitability:core earnings ROE 20.3% and net-income ROE 23.0% (trailing 12 months) — genuinely strong for a P&C insurer. ROIC ~29% TTM, net margin ~14% TTM.
Cash flow: operating CF $5.92B FY25, capex only −$169M → FCF ~$5.75B (FCF yield ~15%). Insurers convert well; buybacks and dividends are amply covered.
Balance sheet: total debt $4.37B, net debt $4.24B, net-debt/EBITDA 0.75× — modest leverage. Book value per diluted share $66.58 (ex-AOCI $75.25); the stock trades ~2.0× book.
6. Valuation — priced in or room?
HIG is genuinely cheap on an absolute basis — 9.5× TTM earnings, 10.3× FY25, 10.7× FY26E, 9.7× FY27E, ~9.0× FY28E, P/B 2.0×, EV/EBITDA 7.4×, FCF yield ~15%. For a 20% core-ROE compounder that is not expensive. But cheap for an insurer is normal: the sector structurally trades at low earnings multiples because earnings are cyclical and CAT-exposed, so a low P/E is not by itself a mispricing. The binding fact is that at $137.85 the stock is right on the Street's $150.38 consensus (high $165, low $135) — meaning the market already credits the quality. Our base-case $150 is deliberately in line: we find no dislocation to exploit. A reverse read: today's price implies roughly the mid-single-digit revenue / high-single-digit EPS path the Street already models — fairly, not cheaply, valued. Verdict: fairly valued, not a bargain — hence Watch, not Buy.
7. Technicals (from the tech block)
Trend:flat / mildly up. $137.85 sits just above the 50-DMA ($132.59) and 200-DMA ($133.90), with the two averages nearly on top of each other — a rangebound, not a trending, posture. MACD +0.77 (mildly positive).
Location:−3.9% off the 52-week high ($143.53) and +15.1% off the 52-week low ($119.73) — mid-to-upper range, shallow max drawdown (−3.9%).
Momentum: RSI(14) 71.8 — overbought (>70). This is a near-term caution flag: the stock has run into the top of its range and is stretched, which argues against chasing here.
Relative strength (the tell): HIG +8.9% 12-mo vs SPY +20.6% and QQQ +30.3%; +2.4% 3-mo vs SPY +13.7%. HIG has materially lagged both the market and tech over the past year — consistent with a defensive, low-beta insurer in a risk-on tape.
Read: technicals are neutral-to-cautious — a rangebound name that is currently overbought and lagging the market. No trend to ride; if adding, waiting for RSI to cool toward the rising 50-DMA (~$133) is the lower-risk entry.
8. Moat & competitive position
HIG's edge is underwriting discipline and distribution, not a structural monopoly. Its moat is a rare-for-insurance combination of (1) scale and data in commercial lines — especially workers' comp and small-commercial, where decades of loss data and agent relationships compound into pricing accuracy; (2) a sub-90 underlying combined ratio, i.e. it makes money on underwriting before investment income, which many peers cannot claim consistently; and (3) diversification across commercial P&C, personal lines, and employee benefits that smooths the cycle. This is a durable operating moat, not a growth moat — it protects returns, it does not create acceleration.
Peer set (market cap, from FMP): AIG $42.1B (closest large diversified comp), Arch Capital $35.7B, Sun Life $44.1B, Berkshire Hathaway $1.10T (the giant of the group), Aegon $13.0B, Equitable Holdings $12.4B, Old Republic $10.2B, Enstar $5.0B, Goosehead $1.3B. HIG's ~9.5× earnings and 20% core ROE are competitive-to-favorable within the diversified-insurer set; it neither commands nor deserves a growth premium.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-led and disciplined — $617M returned in Q1'26 ($450M buybacks + $167M dividends), on top of ~$1.6B buyback + ~$0.59B dividends in FY25. Dividend $2.32/yr (~1.7% yield), payout ratio ~16% — plenty of coverage. Modest leverage (net-debt/EBITDA 0.75×). This is textbook mature-insurer capital management: underwrite for profit, invest the float, return the excess.
Insider activity: the sampled window (2026-03 to 2026-05) shows routine option-exercise-and-sell and in-kind tax withholding by officers (e.g. President A. Tooker exercised options at $49.01 and sold at $135.13 on 2026-05-27) — normal executive diversification, not a discretionary alarm cluster.
Management's own guidance (half-weighted — their book): The SEC 8-K/Q1'26 earnings release (filed 2026-04-23) is a real earnings release. Management's own framing: CEO Christopher Swift called Q1'26 "strong" with core earnings of $866M and a trailing-12-month core-earnings ROE of 20.3%, describing The Hartford as "a proven and consistent performer" and "an underwriting company that consistently delivers with discipline." CFO Beth Costello highlighted 6% Business Insurance written-premium growth, an 89.2 underlying combined ratio, a 4.7-point Personal Insurance underlying improvement, and strong net investment income. Note: the release is a results narrative and does not contain hard forward numeric guidance (no explicit FY revenue/EPS target) — so treat this as management's self-interested tone (positive, half-weighted), not as quantified guidance. Quantified forward guidance was not available in the filing.
10. Catalysts & what to watch
Next earnings: 2026-07-23 (Q2'26; Street EPS $3.24, revenue ~$7.04B). Key lines: Business Insurance premium growth and underlying combined ratio, and CAT losses for the quarter.
Catastrophe experience: the single biggest swing factor each quarter — a heavy hurricane/wildfire/winter-storm season compresses earnings fast (Q1'26 carried $230M CAT losses; Q1'25 carried $467M from the California wildfires).
Prior-year reserve development (PYD): favorable PYD has flattered results; Q1'26 PYD fell to just +$5M (vs +$90M a year earlier) and included a $70M charge for legacy 1970s–80s sexual-abuse liabilities — watch for further legacy top-ups.
Net investment income: higher-for-longer rates and alternative-investment (LP) returns are a tailwind; a rate cut cycle would trim reinvestment yields.
Personal Insurance competition: management flagged a "competitive market" pressuring personal-lines growth — watch the growth-vs-margin trade-off.
Thesis tripwires (what would change the call): a valuation dislocation (a CAT-driven selloff toward the low-$120s would flip Watch→Buy on the cheaper multiple); two straight quarters of underlying combined ratio drifting above 92; a large adverse reserve charge; or a sustained rate-cut path compressing investment income.
11. Key risks
Catastrophe volatility (structural): a severe CAT year can wipe out a quarter's underwriting profit — the defining risk of any P&C insurer.
Reserve-development / legacy liability: the legacy asbestos/environmental run-off plus emerging 1970s–80s sexual-abuse exposures (a $70M Q1'26 top-up) can require adverse reserve charges.
Cyclical / competitive pricing: commercial and personal-lines pricing cycles turn; management already flags a competitive personal-lines market pressuring growth.
Interest-rate sensitivity: a meaningful share of earnings is net investment income; a falling-rate cycle trims reinvestment yields, and AOCI marks on the bond portfolio pressure book value.
No valuation edge / no expert conviction: the stock trades on top of consensus with 0 KB claims — there is simply no informational or valuation advantage to underwrite a high-conviction buy here.
12. Verdict, position sizing & monitoring
Watch. The Hartford is a genuinely well-run, cheap (9.5× TTM), low-beta P&C-plus-benefits insurer earning a 20% core ROE with disciplined capital return — a quality operator. But three things keep it a Watch rather than a Buy: (1) it trades right on the Street's $150 target, so our honest base case is only ~+9% upside; (2) it is overbought near-term (RSI 72) and has lagged the market badly (+8.9% vs SPY +20.6% over 12 months); and (3) there is zero expert coverage in the Synthos KB, so nothing supplements the fundamentals. The quality is real; the entry edge is not.
Sizing: if owned, a small ~1–2% defensive/income sleeve — ballast and yield, not a conviction position. New money has no urgency; a CAT-driven pullback toward the low-$120s would be a more attractive, cheaper entry and would warrant a Watch→Buy revisit.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-23). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $137.85.
Single biggest risk: the catastrophe / reserve-development tail — a bad CAT season or an adverse legacy-liability charge is what turns a steady year into a poor one.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — no expert voices cover HIG in the Synthos KB. This note is explicitly fundamentals- and quant-driven; no conviction is claimed from expert breadth, and no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
Segmentation caveat: FMP's product/geographic segmentation for HIG is stale (2011–2013 / 2022) and was not used for the current mix; the FY25 financials and the Q1'26 SEC release were used instead.
Management caveat: the Q1'26 earnings-release language is management's own, self-interested tone (half-weighted); it contained no quantified forward guidance.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").